What the FDA labels say about taking them together
Lonapegsomatropin and somatropin
Lonapegsomatropin's FDA label of July 23, 2026 names somatropin in its contraindications section; the somatropin labels PlainMeds reads (4) do not name lonapegsomatropin. The lonapegsomatropin label: “… cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11βHSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11βHSD-1 and …”
Check it at the source: the lonapegsomatropin FDA label on DailyMed (effective July 23, 2026); the somatropin FDA label on DailyMed (effective August 20, 2026, Eli Lilly and Company).
What does the lonapegsomatropin label say about somatropin?
Lonapegsomatropin label, contraindicationsCONTRAINDICATIONS SKYTROFA is contraindicated in patients with: Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin [see Warnings and Precautions (5.1) ].
Lonapegsomatropin label, drug interactionsReplacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11βHSD-1. … Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA [see ]
Lonapegsomatropin label, warnings and precautionsIncreased risk of a second neoplasm in childhood cancer survivors treated with somatropin – in particular meningiomas in patients treated with radiation to the head for their first neoplasm ( 5.3 ).
Source: FDA drug label (Skytrofa), Ascendis Pharma Endocrinology, Inc., effective July 23, 2026 (SPL set 9229f871-bc61-4ddc-8122-d126d40e36ac), via openFDA; the full label on DailyMed
What does the somatropin label say about lonapegsomatropin?
Somatropin's label (effective August 20, 2026) and its 3 other brand-application labels do not name lonapegsomatropin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (HUMATROPE), Eli Lilly and Company, effective August 20, 2026 (SPL set a774e1ae-3997-49ee-8b0e-99a2b315d409), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lonapegsomatropin | Somatropin | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $752.22 per cartridge 5 mg cartridge |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once